… Our results demonstrate that C3435T polymorphism of the MDR-1 gene significantly
affected the pharmacokinetics of CLP, CLPM and clopi-H4 metabolites. This may be related to …

… In both the treatment groups, carriage of CYP2C19*2 and ABCB1 C3435T … CYP2C19*2 is
a determinant for the formation of the active metabolite of clopidogrel and its antiplatelet effects…

… Pharmacokinetics and pharmacodynamics of paclitaxel with … Effect of CYP2C19
polymorphism on nelfinavir to M8 … The influence of C3435T polymorphism of ABCB1 gene on …

… Genetic polymorphisms of ABCB1 can lead to variations in P-… an influence of CYP2C19 and
CYP2B6, but not of ABCB1 38… Pharmacokinetics, pharmacodynamics and tolerability might …

… Effects of genetic polymorphism of MDR1 on the expression of P-glycoprotein in human tissues
and in vivo pharmacokinetics and pharmacodynamics … in 14 protein, CYP2C19, including …

… Enrolled subjects were also genotyped with respect to the following single nucleotide
polymorphisms: CYP3A5 *3 and *6, ABCB1 C3435T, and PON1 rs622 (A/G), as previously …

… the role of ABCB1 polymorphisms in drug pharmacokinetics and pharmacodynamics. Because
… , the C1236T, G2677T/A and C3435T polymorphisms had no effect on kinetics [136]. One …

… Furthermore, it was previously reported that the ABCB1 polymorphism (C3435T) affects
the … genotypes could significantly influence pharmacodynamic effects such as antiplatelet …

… Our aim was to evaluate the effect of genetic polymorphisms in … on agomelatine
pharmacokinetics and pharmacodynamics. … of CYP2C9, CYP2C19 and ABCB1 among races …

… affect both pharmacokinetics and pharmacodynamics, such … that CYP2C19*2 and CYP2C19*3
genetic polymorphisms … of C3435T polymorphism on the pharmacokinetics parameters of …